<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02288975</url>
  </required_header>
  <id_info>
    <org_study_id>CytoSorb-2014</org_study_id>
    <nct_id>NCT02288975</nct_id>
  </id_info>
  <brief_title>Adsorbtion of Cytokines Early in Septic Shock: the ACESS Study</brief_title>
  <official_title>The Effect of Early Cytokine Absorption on the Systemic Inflammatory Response Syndrome and Organ Dysfunction in the First 48 Hours of Septic Shock</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Zsolt Molnár, MD, PhD, DEAA</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Szeged University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of the study is to investigate the effect of CytoSorb® treatment within the first 48
      hours of septic shock on organ dysfunction, microcirculation and on the cytokine storm as
      monitored by leukocyte activation and inflammatory mediators.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>October 2014</start_date>
  <completion_date type="Actual">December 2017</completion_date>
  <primary_completion_date type="Actual">December 2017</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Control</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Cytokine response</measure>
    <time_frame>First 48 hours of septic shock</time_frame>
    <description>Cytokine response: procalcitonin, C-reactive protein, interleukin-1, interleukin-1ra, interleukin-6, interleukin-8, interleukin-10, Tumor Necrosis Factor- α</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Organ dysfunctions</measure>
    <time_frame>First 48 hours of septic shock</time_frame>
    <description>Organ dysfunctions: SOFA-scores, neurologic function (Glasgow coma scale), hemodynamic function (PiCCO parameters, ScvO2, lactate, dCO2), pulmonary function (gas exchange, pulmonary mechanics, Acute Respiratory Distress Syndrome classification (BERLIN)), renal function (KDIGO-, RIFLE-scores), gastrointestinal function (liver, GIT function, hematology (hemostasis, qualitative blood count)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Leukocyte function</measure>
    <time_frame>First 48 hours of septic shock</time_frame>
    <description>Leukocyte function: heterogeneity of leukocyte cell population in the bloodstream, T-cell activation and apoptosis, leukocyte inflammatory markers expression</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Microcirculation</measure>
    <time_frame>First 48 hours of septic shock</time_frame>
    <description>Microcirculation: orthogonal polarization spectroscopy (OPS), gastric tonometry</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Length of intensive care unit stay,</measure>
    <time_frame>First 48 hours of septic shock</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Length of hospital stay</measure>
    <time_frame>First 48 hours of septic shock</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Mortality</measure>
    <time_frame>First 48 hours of septic shock</time_frame>
  </other_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Actual">20</enrollment>
  <condition>Sepsis</condition>
  <condition>Septic Shock</condition>
  <arm_group>
    <arm_group_label>CytoSorb</arm_group_label>
    <description>Patients with septic shock will get routine ICU care supported by CytoSorb® treatment.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control</arm_group_label>
    <description>Patients with septic shock will get routine ICU care.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>CytoSorb 300ml device (3804606CE01)</intervention_name>
    <arm_group_label>CytoSorb</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        ICU patients with septic shock of medical origin
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Signs of hypoperfusion: serum lactate &gt;2 mmol/L, low central venous oxygen saturation
             (ScvO2) (&lt;70%) or high ScvO2 (&gt;85%), metabolic acidosis, oligo-anuria, high
             venous-to-arterial CO2-gap (dCO2 &gt;6 mm Hg)

          -  Hemodynamic support with vasopressors

          -  Procalcitonin level ≥ 3 ng/ml

          -  Invasive hemodynamic monitoring

          -  Written informed content

        Exclusion Criteria:

          -  Patients under 18 years

          -  Pregnancy (bHCG test positivity)

          -  Surgical intervention in context with the septic insult

          -  New York Heart Association IV heart failure

          -  Acute coronary syndrome

          -  Need for acute or chronic hemodialysis

          -  Acute haematological malignancies

          -  Cardiogenic shock

          -  Post cardiopulmonary resuscitation care

          -  Immunosuppression, systemic steroid therapy (&gt;10mg prednisolon/day)

          -  Human immunodeficiency virus infection (HIV) and active AIDS

          -  Patients with donated organs

          -  Thrombocytopenia (&lt;20.000/ml)

          -  More than 10%-of body surface area with third degree burn
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Department of Anaesthesiology and Intensive Therapy</name>
      <address>
        <city>Szeged</city>
        <state>Csongrád</state>
        <zip>H-6725</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Hungary</country>
  </location_countries>
  <verification_date>March 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 5, 2014</study_first_submitted>
  <study_first_submitted_qc>November 12, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 13, 2014</study_first_posted>
  <last_update_submitted>March 26, 2018</last_update_submitted>
  <last_update_submitted_qc>March 26, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">March 27, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Szeged University</investigator_affiliation>
    <investigator_full_name>Zsolt Molnár, MD, PhD, DEAA</investigator_full_name>
    <investigator_title>Ph.D. student; Department of Anaesthesiology and Intensive Therapy</investigator_title>
  </responsible_party>
  <keyword>hemoadsorption</keyword>
  <keyword>extracorporeal blood purification</keyword>
  <keyword>CytoSorb</keyword>
  <keyword>hemofiltration</keyword>
  <keyword>SIRS</keyword>
  <keyword>sepsis</keyword>
  <keyword>septic shock</keyword>
  <keyword>membranes</keyword>
  <keyword>ICU</keyword>
  <keyword>dialysis</keyword>
  <keyword>adsorption</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sepsis</mesh_term>
    <mesh_term>Shock</mesh_term>
    <mesh_term>Shock, Septic</mesh_term>
    <mesh_term>Systemic Inflammatory Response Syndrome</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

